CEACAM1 Inhibitors
The class of CEACAM1 inhibitors comprises a diverse array of compounds that modulate the expression and activity of CEACAM1, a cell adhesion molecule with implications in various cellular processes. These inhibitors can either directly target CEACAM1 or indirectly influence its expression by impacting specific signaling pathways. One group of inhibitors includes antagonists of PPARγ, such as GW9662 and T0070907. PPARγ is a transcription factor known to regulate CEACAM1 expression, and these inhibitors suppress its activity, leading to decreased CEACAM1 expression. This suggests a direct link between PPARγ and CEACAM1 modulation. Additionally, inhibitors targeting the PI3K/AKT pathway, such as Wortmannin, LY294002, and PI-103, indirectly inhibit CEACAM1 by disrupting this crucial signaling cascade. The PI3K/AKT pathway plays a significant role in regulating CEACAM1, and inhibiting it can lead to downstream effects that negatively impact CEACAM1 expression.
The MAPK/ERK pathway is another critical signaling pathway implicated in CEACAM1 regulation. Inhibitors like U0126 and PD0325901 target MEK, a key component of this pathway, leading to downstream effects that negatively impact CEACAM1 expression. Furthermore, inhibitors of specific kinases, such as AG-1024 (IGF-1R inhibitor), PP2 (Src family kinase inhibitor), and AG-490 (JAK2 inhibitor), showcase the diversity of pathways that can indirectly regulate CEACAM1 expression. Rapamycin and NSC 23766 represent inhibitors that target mTOR and Rac1, respectively, providing alternative strategies for modulating CEACAM1 expression. In conclusion, the diverse array of CEACAM1 inhibitors presented here highlights the intricate regulatory networks influencing CEACAM1 expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is a selective antagonist of PPARγ. Indirectly, it inhibits CEACAM1 by antagonizing PPARγ, a transcription factor known to regulate CEACAM1 expression. The suppression of PPARγ activity by GW9662 can lead to decreased CEACAM1 expression, suggesting a regulatory role of PPARγ in CEACAM1 modulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinase (PI3K). Indirectly, it inhibits CEACAM1 by disrupting the PI3K/AKT pathway, a signaling cascade in which PI3K plays a pivotal role. Inhibition of PI3K by Wortmannin can lead to downstream effects that negatively impact CEACAM1 expression, highlighting the role of the PI3K/AKT pathway in CEACAM1 regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective inhibitor of phosphoinositide 3-kinase (PI3K). Indirectly, it inhibits CEACAM1 by disrupting the PI3K/AKT pathway, a signaling cascade in which PI3K plays a crucial role. Inhibition of PI3K by LY294002 can lead to downstream effects that negatively impact CEACAM1 expression, emphasizing the regulatory role of the PI3K/AKT pathway in CEACAM1 modulation. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
AG-1024, also known as tyrphostin, is an inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). Indirectly, it inhibits CEACAM1 by disrupting the IGF-1R signaling pathway, where IGF-1R is a key player. Inhibition of IGF-1R by AG-1024 can lead to downstream effects that negatively impact CEACAM1 expression, emphasizing the regulatory role of the IGF-1R pathway in CEACAM1 modulation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. Indirectly, it inhibits CEACAM1 by disrupting Src kinase-dependent signaling pathways. Inhibition of Src family kinases by PP2 can lead to downstream effects that negatively impact CEACAM1 expression, underscoring the regulatory role of Src kinases in CEACAM1 modulation. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490, also known as tyrphostin B42, is a selective inhibitor of Janus kinase 2 (JAK2). Indirectly, it inhibits CEACAM1 by disrupting the JAK2/STAT signaling pathway, where JAK2 is a key player. Inhibition of JAK2 by AG-490 can lead to downstream effects that negatively impact CEACAM1 expression, highlighting the regulatory role of the JAK2/STAT pathway in CEACAM1 modulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Indirectly, it inhibits CEACAM1 by disrupting the mTOR pathway, a central regulator of cell growth and proliferation. Inhibition of mTOR by Rapamycin can lead to downstream effects that negatively impact CEACAM1 expression, demonstrating the regulatory role of the mTOR pathway in CEACAM1 modulation. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual inhibitor of PI3K and mTOR. Indirectly, it inhibits CEACAM1 by disrupting both the PI3K and mTOR pathways. Inhibition of PI3K and mTOR by PI-103 can lead to downstream effects that negatively impact CEACAM1 expression, highlighting the interconnected regulatory roles of the PI3K and mTOR pathways in CEACAM1 modulation. | ||||||
T0070907 | 313516-66-4 | sc-203287 | 5 mg | $141.00 | 1 | |
T0070907 is a selective antagonist of PPARγ. Indirectly, it inhibits CEACAM1 by antagonizing PPARγ, a transcription factor known to regulate CEACAM1 expression. The suppression of PPARγ activity by T0070907 can lead to decreased CEACAM1 expression, suggesting a regulatory role of PPARγ in CEACAM1 modulation. | ||||||